Economic burden of epilepsy among the privately insured in the US.

PharmacoEconomics
Jasmina I IvanovaSue Caleo

Abstract

The direct cost burden of epilepsy in the US from a third-party payer perspective has not been evaluated. Furthermore, no study has quantified the indirect (work-loss) cost burden of epilepsy from an employer perspective in the US. To assess the annual direct costs for privately insured US patients diagnosed with epilepsy, and indirect costs for a subset of employees from an employer perspective. A retrospective analysis of a claims database for the privately insured, including employee disability claims from 1999 through 2005 and comprising 17 US companies, was conducted. A total of 4323 patients aged 16-64 years (including 1886 employees) with at least one epilepsy diagnosis (International Classification of Diseases, 9th edition, Clinical Modification [ICD-9-CM] code 345.x) over the period 1999-2004 were included. The control group was a demographically matched cohort of randomly chosen beneficiaries without an epilepsy diagnosis. All had continuous health coverage during 2004 (baseline) and 2005 (study period). Main outcome measures included annual direct (medical and pharmaceutical) costs and, for employees, indirect (disability and medically related absenteeism) and total costs for the study period. Wilcoxon rank-sum tests...Continue Reading

References

Mar 1, 1996·Epilepsy Research·M I MurrayI E Leppik
Apr 18, 2008·Current Medical Research and Opinion·Lauren J LeeHoward G Birnbaum
May 21, 2008·PharmacoEconomics·Adam StrzelczykHajo M Hamer
Sep 12, 2008·Journal of Occupational and Environmental Medicine·Alan G WhiteJeff Schein

❮ Previous
Next ❯

Citations

Mar 5, 2013·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·J ZeidlerJ-M Graf von der Schulenburg
Feb 25, 2014·Epilepsy & Behavior : E&B·Joyce A CramerMichael S Broder
Dec 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Amy Metcalfe, Nathalie Jetté
Jan 31, 2015·Epilepsy & Behavior : E&B·Joyce A CramerMichael S Broder
Feb 2, 2013·Acta Neurologica Scandinavica·B KristianL Forsgren
Oct 31, 2014·Annals of Clinical and Translational Neurology·Ruta YardiLara E Jehi
Aug 11, 2015·Epilepsy & Behavior : E&B·Victoria DivinoCharles Makin
Jul 29, 2015·Epilepsia·Charles E Begley, Tracy L Durgin
Oct 27, 2012·Epilepsy & Behavior : E&B·Edward Faught
Apr 18, 2015·Pediatric Neurology·Elena CaronJames W Wheless
Nov 19, 2013·Epilepsy & Behavior : E&B·Joyce A CramerMichael S Broder
Nov 6, 2012·Epilepsy & Behavior : E&B·Andrew N WilnerAndrew Krueger
Mar 25, 2015·Seizure : the Journal of the British Epilepsy Association·Anna H NodaAdam Strzelczyk
Nov 10, 2015·Lancet Neurology·Mark R KeezerJosemir W Sander
Jun 19, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Melissa H RobertsMatthew E Borrego
Oct 9, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Aneta MelaMaciej Niewada
Jun 9, 2018·Nutrients·Anna E KirklandKathleen F Holton
Dec 5, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Zhixiao WangJose E Cavazos
Oct 7, 2017·Developmental Medicine and Child Neurology·Lieven LagaeAlysia Battersby

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.